Efficacy and safety of idelalisib for the treatment of indolent B-cell malignancies

Safety and Tolerability of Phosphatidylinositol-3-Kinase (PI3K) Inhibitors in Oncology

(2019) Giuseppe Curigliano et al.   DRUG SAFETY

Targeting PI3K Signaling in Acute Lymphoblastic Leukemia

(2019) Vanessa Sanchez et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

DYNAMO: A Phase II Study of Duvelisib (IPI-145) in Patients With Refractory Indolent Non-Hodgkin Lymphoma

(2019) Ian W. Flinn et al.   JOURNAL OF CLINICAL ONCOLOGY

Idelalisib for optimized CD19-specific chimeric antigen receptor T cells in chronic lymphocytic leukemia patients

(2019) Sophia Stock et al.   INTERNATIONAL JOURNAL OF CANCER

Final Results of a Randomized, Phase III Study of Rituximab With or Without Idelalisib Followed by Open-Label Idelalisib in Patients With Relapsed Chronic Lymphocytic Leukemia

(2019) Jeff P. Sharman et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase I study of taselisib in Japanese patients with advanced solid tumors or hormone receptor-positive advanced breast cancer

(2018) Kenji Tamura et al.   CANCER SCIENCE

A Phase I Trial of the PI3K Inhibitor Buparlisib Combined With Capecitabine in Patients With Metastatic Breast Cancer

(2018) Autumn J. McRee et al.   Clinical Breast Cancer

Phosphatidylinositol 3-Kinase α–Selective Inhibition With Alpelisib (BYL719) in PIK3CA-Altered Solid Tumors: Results From the First-in-Human Study

(2018) Dejan Juric et al.   JOURNAL OF CLINICAL ONCOLOGY

Critical molecular pathways in CLL therapy

(2018) Gerardo Ferrer et al.   MOLECULAR MEDICINE

Pre-clinical activity of targeting the PI3K/Akt/mTOR pathway in Burkitt lymphoma

(2018) Maria Bhatti et al.   Oncotarget

Management of adverse events associated with idelalisib treatment in chronic lymphocytic leukemia and follicular lymphoma: A multidisciplinary position paper

(2018) Antonio Cuneo et al.   HEMATOLOGICAL ONCOLOGY

The phase 3 DUO trial: duvelisib vs ofatumumab in relapsed and refractory CLL/SLL

(2018) Ian W. Flinn et al.   BLOOD

Phase Ib dose-finding study of abiraterone acetate plus buparlisib (BKM120) or dactolisib (BEZ235) in patients with castration-resistant prostate cancer

(2017) Christophe Massard et al.   EUROPEAN JOURNAL OF CANCER

Incidence and management of toxicity associated with ibrutinib and idelalisib: a practical approach

(2017) Iris de Weerdt et al.   HAEMATOLOGICA

Phosphatidylinositol 3-Kinase Inhibition by Copanlisib in Relapsed or Refractory Indolent Lymphoma

(2017) Martin Dreyling et al.   JOURNAL OF CLINICAL ONCOLOGY

Buparlisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal, hormone receptor-positive, HER2-negative, advanced breast cancer (BELLE-2): a randomised, double-blind, placebo-controlled, phase 3 trial

(2017) José Baselga et al.   LANCET ONCOLOGY

A Phase I Dose‐Escalation Study of the Safety and Pharmacokinetics of Pictilisib in Combination with Erlotinib in Patients with Advanced Solid Tumors

(2017) Stephen Leong et al.   ONCOLOGIST

A Multi-Arm Phase I Study of the PI3K/mTOR Inhibitors PF-04691502 and Gedatolisib (PF-05212384) plus Irinotecan or the MEK Inhibitor PD-0325901 in Advanced Cancer

(2017) Zev A. Wainberg et al.   Targeted Oncology

A Phase Ib Study of the Dual PI3K/mTOR Inhibitor Dactolisib (BEZ235) Combined with Everolimus in Patients with Advanced Solid Malignancies

(2017) Trisha M. Wise-Draper et al.   Targeted Oncology

Incidence and management of toxicity associated with ibrutinib and idelalisib: a practical approach

(2017) Iris de Weerdt et al.   HAEMATOLOGICA

Safety and tolerability of idelalisib, lenalidomide, and rituximab in relapsed and refractory lymphoma: the Alliance for Clinical Trials in Oncology A051201 and A051202 phase 1 trials

(2017) Sonali M Smith et al.   Lancet Haematology

Efficacy and safety of idelalisib in combination with ofatumumab for previously treated chronic lymphocytic leukaemia: an open-label, randomised phase 3 trial

(2017) Jeffrey A Jones et al.   Lancet Haematology

First-in-human phase I study of copanlisib (BAY 80-6946), an intravenous pan-class I phosphatidylinositol 3-kinase inhibitor, in patients with advanced solid tumors and non-Hodgkin's lymphomas

(2016) A. Patnaik et al.   ANNALS OF ONCOLOGY

Phase I dose escalation study of the PI3kinase pathway inhibitor BKM120 and the oral poly (ADP ribose) polymerase (PARP) inhibitor olaparib for the treatment of high grade serous ovarian and breast cancer

(2016) U.A. Matulonis et al.   ANNALS OF ONCOLOGY

Pictilisib PI3Kinase inhibitor (a phosphatidylinositol 3-kinase [PI3K] inhibitor) plus paclitaxel for the treatment of hormone receptor-positive, HER2-negative, locally recurrent, or metastatic breast cancer: interim analysis of the multicentre, placebo-controlled, phase II randomised PEGGY study

(2016) P. Vuylsteke et al.   ANNALS OF ONCOLOGY

Phase 2 study of idelalisib and entospletinib: pneumonitis limits combination therapy in relapsed refractory CLL and NHL

(2016) P. M. Barr et al.   BLOOD

Idelalisib in the management of lymphoma

(2016) C. Y. Cheah et al.   BLOOD

Idelalisib given front-line for treatment of chronic lymphocytic leukemia causes frequent immune-mediated hepatotoxicity

(2016) B. L. Lampson et al.   BLOOD

Phase I Study of Apitolisib (GDC-0980), Dual Phosphatidylinositol-3-Kinase and Mammalian Target of Rapamycin Kinase Inhibitor, in Patients with Advanced Solid Tumors

(2016) S. O. Dolly et al.   CLINICAL CANCER RESEARCH

Efficacy and safety of idelalisib in patients with relapsed, rituximab- and alkylating agent-refractory follicular lymphoma: a subgroup analysis of a phase 2 study

(2016) Gilles Salles et al.   HAEMATOLOGICA

Phase Ia/Ib study of the pan-class I PI3K inhibitor pictilisib (GDC-0941) administered as a single agent in Japanese patients with solid tumors and in combination in Japanese patients with non-squamous non-small cell lung cancer

(2016) Noboru Yamamoto et al.   INVESTIGATIONAL NEW DRUGS

Randomized Open-Label Phase II Trial of Apitolisib (GDC-0980), a Novel Inhibitor of the PI3K/Mammalian Target of Rapamycin Pathway, Versus Everolimus in Patients With Metastatic Renal Cell Carcinoma

(2016) Thomas Powles et al.   JOURNAL OF CLINICAL ONCOLOGY

Idelalisib sensitivity and mechanisms of disease progression in relapsed TCF3-PBX1 acute lymphoblastic leukemia

(2016) S Eldfors et al.   LEUKEMIA

Efficacy and safety of idelalisib in patients with relapsed, rituximab- and alkylating agent-refractory follicular lymphoma: a subgroup analysis of a phase 2 study

(2016) Gilles Salles et al.   HAEMATOLOGICA

Idelalisib-associated Enterocolitis

(2015) Christine Y. Louie et al.   AMERICAN JOURNAL OF SURGICAL PATHOLOGY

Idelalisib-associated Colitis

(2015) Anna-Sophie Weidner et al.   AMERICAN JOURNAL OF SURGICAL PATHOLOGY

Lenalidomide, idelalisib, and rituximab are unacceptably toxic in patients with relapsed/refractory indolent lymphoma

(2015) C. Y. Cheah et al.   BLOOD

Parallel phase Ib studies of two schedules of buparlisib (BKM120) plus carboplatin and paclitaxel (q21 days or q28 days) for patients with advanced solid tumors

(2015) David M. Hyman et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

FDA Approval: Idelalisib Monotherapy for the Treatment of Patients with Follicular Lymphoma and Small Lymphocytic Lymphoma

(2015) B. W. Miller et al.   CLINICAL CANCER RESEARCH

First-in-Human Study of PF-05212384 (PKI-587), a Small-Molecule, Intravenous, Dual Inhibitor of PI3K and mTOR in Patients with Advanced Cancer

(2015) G. I. Shapiro et al.   CLINICAL CANCER RESEARCH

Clinical Pharmacokinetic and Pharmacodynamic Profile of Idelalisib

(2015) Srinivasan Ramanathan et al.   CLINICAL PHARMACOKINETICS

Management of adverse events associated with idelalisib treatment: expert panel opinion

(2015) Steven E. Coutré et al.   LEUKEMIA & LYMPHOMA

IPI-145 antagonizes intrinsic and extrinsic survival signals in chronic lymphocytic leukemia cells

(2014) S. Dong et al.   BLOOD

Idelalisib, an inhibitor of phosphatidylinositol 3-kinase p110 , for relapsed/refractory chronic lymphocytic leukemia

(2014) J. R. Brown et al.   BLOOD

A phase 1 study of the PI3K  inhibitor idelalisib in patients with relapsed/refractory mantle cell lymphoma (MCL)

(2014) B. S. Kahl et al.   BLOOD

Phase Ib Study of Buparlisib plus Trastuzumab in Patients with HER2-Positive Advanced or Metastatic Breast Cancer That Has Progressed on Trastuzumab-Based Therapy

(2014) C. Saura et al.   CLINICAL CANCER RESEARCH

Idelalisib — A PI3Kδ Inhibitor for B-Cell Cancers

(2014) David A. Fruman et al.   NEW ENGLAND JOURNAL OF MEDICINE

PI3Kδ Inhibition by Idelalisib in Patients with Relapsed Indolent Lymphoma

(2014) Ajay K. Gopal et al.   NEW ENGLAND JOURNAL OF MEDICINE

Idelalisib and Rituximab in Relapsed Chronic Lymphocytic Leukemia

(2014) Richard R. Furman et al.   NEW ENGLAND JOURNAL OF MEDICINE

BAY 80-6946 Is a Highly Selective Intravenous PI3K Inhibitor with Potent p110α and p110δ Activities in Tumor Cell Lines and Xenograft Models

(2013) Ningshu Liu et al.   MOLECULAR CANCER THERAPEUTICS

Selective inhibitors of phosphoinositide 3-kinase delta: modulators of B-cell function with potential for treating autoimmune inflammatory diseases and B-cell malignancies

(2012) Kamal D. Puri et al.   Frontiers in Immunology

The phosphoinositide 3'-kinase delta inhibitor, CAL-101, inhibits B-cell receptor signaling and chemokine networks in chronic lymphocytic leukemia

(2011) J. Hoellenriegel et al.   BLOOD

Identification and Characterization of NVP-BKM120, an Orally Available Pan-Class I PI3-Kinase Inhibitor

(2011) S.-M. Maira et al.   MOLECULAR CANCER THERAPEUTICS

CAL-101, a p110  selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability

(2010) B. J. Lannutti et al.   BLOOD

Phosphatidylinositol 3-kinase-  inhibitor CAL-101 shows promising preclinical activity in chronic lymphocytic leukemia by antagonizing intrinsic and extrinsic cellular survival signals

(2010) S. E. M. Herman et al.   BLOOD

The emerging mechanisms of isoform-specific PI3K signalling

(2010) Bart Vanhaesebroeck et al.   NATURE REVIEWS MOLECULAR CELL BIOLOGY